|Table of Contents|

Expression of PD-L1 in tumor cells,tumor-infiltrating immune cells of colorectal cancer and its correlation with clinicopathological features and prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 14
Page:
2660-2665
Research Field:
Publishing date:

Info

Title:
Expression of PD-L1 in tumor cells,tumor-infiltrating immune cells of colorectal cancer and its correlation with clinicopathological features and prognosis
Author(s):
MA Wenjuan1; REN Jianwei2; CHANG Shoufeng3; ZHOU Zubang1
1.Department of Ultrasound;3.Department of Pathology,Gansu Provincial Hospital,Gansu Lanzhou 730000,China;2.The First School of Clinical Medicine,Gansu University of Traditional Chinese Medicine，Gansu Lanzhou 730000,China.
Keywords:
colorectal cancer; PD-L1; tumor-infiltrating immune cell; prognosis
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2023.14.016
Abstract:
Objective:To investigate the expression of programmed death -ligand (PD-L1) in tumor cells (TC),tumor-infiltrating immune cells (TIIC) of colorectal cancer (CRC) and its correlation with clinicopathological features and prognosis.Methods:Immunohistochemistry was used to dectect the expression of PD-L1 in TC and TIIC of 72 CRC cases，underwent radical operation and pathologically verified from 2018 to 2021 in our hospital.The relationship between expression of PD-L1 in CRC and clinicopathologic characteristics,and analyzed relationship of overall survival time in all patients was analyzed.Results:The positive rate of TC PD-L1 in 72 colorectal cancer patients was 6.9%,which was correlated with the degree of tumor differentiation.The positive rate of PD-L1 in TIIC was 48.6%,which was related to the preoperative serum levels of CEA and CA199.Kaplan-meier and Log-rank results showed that OS was associated with differentiation degree,lymph node metastasis,liver metastasis and TIIC PD-L1 expression (P＜0.05).The OS of TIIC PD-L1 positive patients was longer than that of TIIC PD-L1 negative patients.Cox univariate and multivariate regression analysis showed that differentiation degree,lymph node metastasis,liver metastasis and TIIC PD-L1 expression were independent prognostic factors affecting OS in CRC patients.Conclusion:PD-L1 is expressed in TC and TIIC of CRC,and the OS of TIIC PD-L1 positive patients is longer than that of TIIC PD-L1 negative patients.The expression of TIIC PD-L1 can better reflect the tumor immune microenvironment,and provide a reference for predicting the efficacy of immunotherapy and prognosis of CRC.

References:

［1］FERLAY J,ERVIK M,LAM F,et al.Global cancer observatory:cancer today［EB/OL］.(2020-12-01)［2022-12-11］.https://gco.iarc.fr/today.
［2］ZHENG R,ZHANG S,ZENG H,et al.Cancer incidence and mortality in China,2016［J］.Journal of The National Cancer Center,2022,2(1):1-9.
［3］PICARD E,VERSCHOOR CP,MA GW,et al.Relationships between immune landscapes,genetic subtypes and responses to immunotherapy in colorectal cancer［J］.Frontiers In Immunology,2020,11:369.
［4］IJSSELSTEIJN ME,SANZ-PAMPLONA R,HERMITTE F,et al.Colorectal cancer:a paradigmatic model for cancer immunology and immunotherapy［J］.Molecular Aspects of Medicine,2019,69:123-129.
［5］WU X,GU Z,CHEN Y,et al.Application of PD-1 blockade in cancer immunotherapy［J］.Comput Struct Biotechnol J,2019,17:661-674.
［6］PIAWAH S,VENOOK AP.Targeted therapy for colorectal cancer metastases:a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer［J］.Cancer,2019,125(23):4139-4147.
［7］Food and drug administration.FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer［EB/OL］.(2020-06-29)［2022-12-11］.https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer.
［8］BENSON AB,VENOOK AP,AL-HAWARY MM,et al.NCCN guidelines forcolon cancer,Version 1.2022［EB/OL］.(2022-02-25)［2022-12-11］.https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428.
［9］TANG M,ZHENG Z,SHANG J,et al.Risk analysis of positive PD-L1 expression and clinicopathological features and survival prognosis in patients with colorectal cancer:systematic review and meta-analysis［J］.Journal of Healthcare Engineering,2022,2022:8212486.
［10］MOLLER K,BLESSIN NC,HOFLMAYER D,et al.High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer［J］.Acta Oncologica,2021,60(9):1210-1217.
［11］顾丽琴,濮阳隆翔,谢芳.PD-1/PD-L1参与NK细胞调控抗肿瘤免疫的作用机制［J］.临床与实验病理学杂志,2022,38(4):452-455. GU LQ,PU YLX,XIE F.PD-1/PD-L1 is involved in the mechanism of NK cells regulating anti-tumor immunity［J］.J Clin Exp Pathol,2022,38(4):452-455.
［12］PAVER EC,COOPER WA,COLEBATCH AJ,et al.Programmed death ligand-1(PD-L1) as a predictive marker for immunotherapy in solid tumours:a guide to immunohistochemistry implementation and interpretation［J］.Pathology,2021,53(2):141-156.
［13］冯昌银,郑巧灵,黄建平,等.结直肠癌肿瘤原发灶与肝脏转移灶中PD-L1表达的差异性［J］.临床与实验病理学杂志,2018,34(12):5. FEN CY,ZHENG QL,HUANG JP,et al.Differences in PD-L1 expression between primary colorectal cancer and liver metastases［J］.J Clin Exp Pathol,2018,34(12):5.
［14］LIU R,KE P,YU Y,et al.Prognostic value of immunoscore and PD-L1 expression in metastatic colorectal cancer patients with different RAS status after palliative operation［J］.BioMed Research International,2018,2018:1-8.
［15］PYO JS,KO SH,KO YS,et al.Clinicopathological significance of PD-L1 expression in colorectal cancer:impact of PD-L1 expression on pFOXO1 expression［J］.Pathology,Research and Practice,2020,216(2):152764.
［16］CHEN YL,WANG GX,LIN BA,et al.MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer［J］.Cell Biology International,2020,44(5):1224-1236.
［17］VALENTINI AM,PINTO FD,CARIOLA F,et al.PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments［J］.Oncotarget,2018,9(9):8584-8596.
［18］ZHONG G,PENG C,CHEN Y,et al.Expression of STING and PD-L1 in colorectal cancer and their correlation with clinical prognosis［J］.Int J Clin Exp Pathol,2018,11(3):1256-1264.
［19］MASUGI Y,NISHIHARA R,YANG J,et al.Tumour CD274 (PD-L1) expression and T cells in colorectal cancer［J］.Gut,2017,66(8):1463-1473.
［20］WANG L,REN F,WANG Q,et al.Significance of programmed death ligand 1 (PD-L1) Immunohistochemical expression in colorectal cancer［J］.Molecular Diagnosis & Therapy,2016,20(2):175-181.
［21］茅挺,韦琦,汪倩,等.共刺激分子B7-H3和程序性死亡因子配体1在胃肠道恶性肿瘤诊断和预后价值研究［J］.中华实验外科杂志,2022,39(3):548-551. MAO T,WEI Q,WANG Q,et al.Diagnostic and prognostic value of costimulatory molecules b7 homolog 3 protein and programmed death ligand 1 in gastrointestinal malignancies［J］.Chin J Exp Surg,2022,39(3):548-551.
［22］LEE KS,KIM BH,OH HK,et al.Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer:implications for prognosis［J］.Cancer Science,2018,109(9):2957-2969.

Memo

Memo:
甘肃省重点研发计划项目（编号：20YF3FA015）
Last Update: 1900-01-01